Dong-a St Co., Ltd.

Dong-a Pharm. Co., Ltd.

Weon-Bin Im

Sung-Hak Choi

Soon-Hoe Kim

Sun-Ho Choi

Hyun-Jung Sung

Jung-Sang Park

Mi-Yeon Kim

Tae-hyoung Kim

Min-Jung Lee

Kyung-Seok Lee

Ill-Hun Jung

Chong-Hwan Cho

Jae-Sung Yang

Gye-Rim Baek

Yu-Na Chae

Chae-Lim Ryu

Kang-Hun Cho

Ji-Hoon Choi

Jin-Hyuk Kim

Hyung-Keun Lee

Seung-Bum Ha

Cheon-Hyoung Park

Tae-Kyoung Sohn

Ju-Hee Sohn

Yoon-Jung Kim

Seung-Hyun Song

Jun-Hwan Moon

Ho-Sang Moon

Tae-Hyoung Kim

A novel peptide analog of acylated oxyntomodulin and its uses are disclosed. A pharmaceutical composition containing the novel peptide analog is useful and effective for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptide analog and a composition containing the peptide analog are superior to those of wild-type oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition containing the peptide analog is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.

Acylated oxyntomodulin peptide analog

The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.

The present disclosure relates to a novel tetrahydropyridine derivative compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, methods for preparing the compounds, methods for inhibiting UDP-3-O&#x2014;(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC), methods for treating Gram-negative bacterial infections, the use of the compounds for the preparation of therapeutic medicaments for treating Gram-negative bacterial infections, and pharmaceutical compositions for prevention or treatment of Gram-negative bacterial infections, which contain the compounds. The compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure can exhibit excellent effects on the treatment bacterial infections.

Tetrahydropyridine derivatives and their use as antibacterial agents

Provided are biphenyl derivatives having the structure of Formula 1: stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein Ris hydrogen, halogen, hydroxy, substituted or unsubstituted C-Calkyl, or C-Calkoxy; R, Rand Rare each independently hydrogen, halogen, substituted or unsubstituted amino, nitro, cyano, hydroxy, substituted or unsubstituted C-Calkyl, substituted or unsubstituted C-Calkoxy, or &#x2014;C(O)R; Ris hydrogen or C-Calkyl; n is 0 or 1; and Ris hydrogen or amino, methods for preparing the same, and a pharmaceutical composition containing the same. The biphenyl derivatives having the structure of Formula 1 act as muscarinic M3 receptor antagonists, and thus are useful for the prevention or treatment of a disease selected from among chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, Alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes.

Biphenyl derivatives and methods for preparing same

The present invention relates to a novel tricyclic benzoxaborole derivative, a preparation method thereof, and use of antibiotics pharmaceutical composition including the same as an active ingredient.

Tricyclic benzoxaborole compound, preparation method and use thereof

The present invention provides a novel benzamide derivative or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a 5-HTreceptor agonist containing the same as an active ingredient. Benzamide derivatives of the present invention have a superior affinity for 5-HTreceptors, a capability to reduce a gastric emptying time and a low toxicity, and consequently are therapeutically effective for the treatment of a variety of diseases associated with 5-HTreceptors.

Benzamide derivatives

Growing community of inventors

Gyeonggi-do, South Korea

Weon-Bin Im